An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Dosis Announces Nationwide Precision Dosing Implementation with DaVita
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
SAN FRANCISCO--(BUSINESS WIRE)--
Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the implementation of its flagship personalized dosing product at DaVita (NYSE: DVA) clinics nationwide. Dosis’s Smart Anemia Manager (SAM) personalizes drug dosing for erythropoiesis-stimulating agents (ESAs), a class of drugs used to treat end-stage renal disease patients with chronic anemia.
Integration of Dosis’s personalized dosing recommendations into DaVita’s anemia management protocols first began in 2019, and over 30 million dialysis treatments have been informed to date.
“We are incredibly excited about the impact of our technology on chronic disease management,” said Shivrat Chhabra, Chief Executive Officer and co-founder of Dosis. “The shift to value-based care is driving the need for precision medicine tools that maximize patient outcomes while reducing the cost of care. DaVita has been a visionary in realizing the potential of precision medicine in this exciting new era.”
Using each dialysis patient’s past ESA doses, hemoglobin levels, and target hemoglobin range, SAM calculates and delivers a personalized dosing recommendation for each patient that helps manage their hemoglobin levels while reducing unnecessary ESA exposure and drug cost. SAM’s personalized dosing recommendations are designed to improve upon conventional one-size-fits-all dosing approaches.
About Dosis Inc.
Dosis Inc. is a San Francisco-based precision medicine software company that was founded with the mission to transform chronic disease management by leveraging advancements in artificial intelligence and control algorithms. With a deep academic history, Dosis uses science, data, patient safety, and clinical evidence to create precision dosing tools. For more information about the technology behind SAM, visit dosisinc.com/platform, and for more information about Dosis, visit dosisinc.com.
about davita kidney care davita kidney care is a division of davita healthcare partners inc., a fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the united states and abroad. a leading provider of dialysis services in the united states, davita kidney care treats patients with chronic kidney failure and end stage renal disease. davita kidney care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. as of march 31, 2015, davita kidney care operated or provided administrative services at 2,197 outpatient dialysis centers located in the united states serving approximately 174,000 patients. the company also operated 93 outpatient dialysis centers located in 10 countries outside the united states. davita kidney care supports numerous programs dedicated to creating positive,
